TD 101

Drug Profile

TD 101

Alternative Names: Pachyonychia congenita siRNA; Reveker; sdTD-K6a.513a.12; siRNA sdTD101; TD-K6a.513a.12; TD101

Latest Information Update: 26 Apr 2016

Price : $50

At a glance

  • Originator TransDerm
  • Developer International Pachyonychia Congenita Consortium; PC Project; TransDerm
  • Class Skin disorder therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pachyonychia congenita

Most Recent Events

  • 20 Apr 2016 No recent reports on development identified - Preclinical for Pachyonychia congenita in USA (Topical)
  • 17 Jan 2008 Phase-I clinical trials in Pachyonychia congenita in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top